Tilray Brands, Inc. (TLRY)
- Previous Close
1.7800 - Open
1.7700 - Bid 1.7300 x 3900
- Ask 1.7600 x 2400
- Day's Range
1.7400 - 1.7800 - 52 Week Range
1.5000 - 3.4000 - Volume
3,783,473 - Avg. Volume
34,768,501 - Market Cap (intraday)
1.441B - Beta (5Y Monthly) 2.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.36
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
www.tilray.com1,600
Full Time Employees
May 31
Fiscal Year Ends
Sector
Recent News: TLRY
Performance Overview: TLRY
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLRY
Valuation Measures
Market Cap
1.47B
Enterprise Value
1.73B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.71
Price/Book (mrq)
0.44
Enterprise Value/Revenue
2.33
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-47.35%
Return on Assets (ttm)
-1.67%
Return on Equity (ttm)
-9.69%
Revenue (ttm)
743.25M
Net Income Avi to Common (ttm)
-351.95M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
225.86M
Total Debt/Equity (mrq)
14.41%
Levered Free Cash Flow (ttm)
-14.88M
Research Analysis: TLRY
Company Insights: TLRY
TLRY does not have Company Insights
Research Reports: TLRY
Cannabis Shares Rally (Again) on Next Incremental Step to Federal Rescheduling
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Fair Isaac's upside fair; Initiating Coverage of GE Vernova; and US cable valuations have tumbled perhaps more than deserved; and Marvell Technology, Tilray Brands, and Yum China.
Tilray Earnings: Slashing Our Fair Value Estimate on Slower Revenue Growth and Margin Contraction
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice TargetFirst Pillar of Germany's Cannabis Legalization Begins April 1; Legal Sales to Come Later
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
RatingPrice Target